Estazolam

CHEMBL285674 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

294.7 g/mol

LogP

1.7

Phase

4

This benzodiazepine medication works by enhancing the calming effects of GABA in the brain to help with falling and staying asleep. It is used for the short-term treatment of insomnia.

Moleküler Ağırlık

294,7400 g/mol

LogP

1,70

TPSA

43,10 Å²

Lipinski RO5

Geçer

Terapötik Alanlar

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Insomnia Breast Cancer Prostate Cancer Colorectal Cancer

Etki Mekanizması

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, …

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

Clc1ccc2c(c1)C(c1ccccc1)=NCc1nncn1-2

InChI

InChI=1S/C16H11ClN4/c17-12-6-7-14-13(8-12)16(11-4-2-1-3-5-11)18-9-15-20-19-10-21(14)15/h1-8,10H,9H2

Molecular Formula

C16H11ClN4

HBD / HBA

- / 3

Döndürülebilir Bağlar

1

Ağır Atomlar

21

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

This benzodiazepine medication works by enhancing the calming effects of GABA in the brain to help with falling and staying asleep. It is used for the short-term treatment of insomnia.

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.

Yes, Estazolam is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL285674. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 3261. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Estazolam PillFYI'da

Yapı

Hızlı Veriler

Formül: C16H11ClN4

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.